News & Updates

New research indicates that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may confer a protective effect against cancers in adults with overweight or obesity regardless of type 2 diabetes status.

Handgrip strength is predictive of all-cause mortality risk in older adults with severe obesity, and this association points to some useful thresholds for reducing the risk of death, suggest the results of a multi-country cohort study.

Receiving a stimulant prescription for attention deficit hyperactivity disorder (ADHD) via telehealth shows no significant impact on the risk for substance use disorder (SUD) but appears to elevate the risk of subsequent stimulant use disorder (stimUD), suggests a study.

Treatment with antipsychotics may lead to a significant glucose homeostasis dysregulation, regardless of exposure time, dose, diagnosis, and weight gain propensity, according to systematic review and meta-analysis.

Patients with type 2 diabetes mellitus (T2DM) who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have lower odds of peptic ulcer disease when compared with insulin users, as shown in a retrospective study.

Combination treatment with the oral, highly selective FGFR4 inhibitor irpagratinib plus atezolizumab has shown promising efficacy in patients with untreated or immune checkpoint inhibitor (ICI)-exposed hepatocellular carcinoma (HCC) with fibroblast growth factor 19 overexpression (FGF19+), while being safe and well tolerated, according to the updated results of the phase II ABSK-011-201 study.

Total dose desensitization is successful in patients with hypersensitivity reactions (HSRs) to chemotherapy, suggests a study.